Back to News
Market Impact: 0.25
Psyence BioMed Plans $5 Mln Cash Investment In PsyLabs For U.S. Ibogaine Program
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureCapital Returns (Dividends / Buybacks)
Psyence BioMed agreed to invest up to $5 million in cash in Psyence Labs and conduct a value-matched share exchange to support a planned U.S. Ibogaine program. The transaction provides funding and corporate alignment for the biotech program, but no clinical, regulatory, or financial-return milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PBM0.55
More News
- Street Calls of The Week
- Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline
- Berkshire Hathaway stock is a haven again as investors flee AI bloodbath while its own portfolio takes a hit amid reshuffling
- Berkshire Makes Record $9.6 Billion Buyback
- Seaport offers preliminary thoughts on Anthropic stock
- argenx reports positive phase 3 data for autoimmune myositis drug